Antibacterial Drugs Market (Drug Class - B - lactams, Quinolones, Macrolides, Tetracycline, Aminoglycoside, Sulfonamide, and Phenicols; Routes of Administration - Enteral and Parenteral; Distribution Channel - Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030

The global antibacterial drugs market for the historical period 2017–2018 and forecast period 2019–2027, high prevalence of infectious diseases, increase in research and developmental activities, and increase in initiatives by government in healthcare sector are the factors projected to drive the global antibacterial drugs market during the forecast period

According to the report, the global antibacterial drugs market was valued at US$ 46.37 Bn in 2018 and is anticipated to expand at a CAGR of 1.5% from 2019 to 2030

Increase in Prevalence of Infectious Diseases: Key Driver

High prevalence of infectious diseases results in increasing number of patient population and rise in the demand for antibacterial drugs, which thereby is responsible for driving the antibacterial drugs market

According to Baylor College of Medicine, infectious diseases are a leading cause of death worldwide, particularly in low income countries, especially in young children.

European Centre for Disease Prevention and Control (ECDC) states that, every year, around three million people in the EU catch a healthcare-associated infection, of whom approximately 50,000 die.

According to National Hospital Ambulatory Medical Care Survey in 2016 in U.S., approximately 280,000, emergency department visits resulted in hospital admission with a principal hospital discharge diagnosis of infectious and parasitic diseases

Increase in geriartic population and increasing number of antibiotic resistance or multi-drug resistant bacterial strains

According to a study published in 2016, titled “Infection in an aging population”, the global population is rapidly aging. Currently, 566 million people are 65 years old worldwide, with estimates of nearly 1.5 billion by 2050, particularly in developing countries. Infections constitute a third of mortality in people 65 years old. Moreover, lengthening life spans correlate with increased time in hospitals or long-term care facilities and exposure to drug-resistant pathogens. Indeed, the risk of nosocomial infections increases with age, independent of duration spent in healthcare facilities.

According to WHO, antibiotic resistant bacteria are responsible for up to 60% of hospital acquired infections in the United States. Resistance means that people with infections are ill for longer periods, and are at greater risk of dying, and that disease epidemics are prolonged.

As per WHO, in 2016, around 490,000 people developed multi-drug resistant tuberculosis globally, and drug resistance is starting to complicate the fight against HIV and malaria, as well.

Therefore, rise in geriatric population, and increasing number of antibiotic resistance or multi-drug resistant bacterial strains are responsible for boosting the growth of the antibacterial drugs market

Rising number of generic drugs for antibacterial activities and patent expiries to Hamper Market

The Generic Drug User Fee Amendments (GDUFA), passed by U.S. Congress in 2012, were intended to speed U.S. Food and Drug Administration approval of new generic drugs, which create competition for brand drugs and reduce drug prices for consumers.

Wide availability of over the counter (OTC) drugs and generic drugs, and number of antibacterial drugs near to off patent is anticipated to lead to a shift from branded drugs to generic ones, which could hamper the antibacterial drugs market from realizing its true revenue potential.

Global Antibacterial Drugs Market: Competitive Landscape

This report profiles major players in the global antibacterial drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global antibacterial drugs market is highly fragmented, with the presence of a number of international as well as regional players

Leading players operating in the global antibacterial drugs market are

• Bayer AG
• Pfizer Inc.
• Sanofi
• GlaxoSmithKline plc.
• Merck & Co., Inc.
• AstraZeneca
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Allergan, 

Key Questions Answered in Global Antibacterial Drugs Market Report

• What is the scope of growth of product companies in the global antibacterial drugs market?
• What will be the Y-o-Y growth of the global antibacterial drugs market between 2019 and 2027?
• What is the influence of changing trends in technologies on the global antibacterial drugs market?
• Will North America continue to be the most profitable market for antibacterial drugs providers?
• Which factors are anticipated to hamper the growth of the global antibacterial drugs market during the forecast period?
• Which are the leading companies in the global antibacterial drugs market?

Global Antibacterial drugs Market – Segmentation

Drug Class

• B-lactam
• Quinolones
• Macrolides
• Tetracyclines
• Aminoglycosides
• Sulfonamides
• Phenicols
• Others

Route of Administration

• Enteral
• Parenteral
• Others

Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Sales

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Chapter 1. Preface

    1.1. Report Scope and Market Segmentation 

    1.2. Research Highlights

    1.3. Assumptions and Acronyms Used

Chapter 2. Research Methodology 

Chapter 3.  Executive Summary 

Chapter 4. Market Overview

    4.1. Product Overview

    4.2. Key Industry Developments 

    4.3. Market Dynamics 

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity Analysis

        4.3.4. Porter’s Five Forces Representation

        4.3.5. Antibacterial Drugs Market- Value Chain Analysis & Supply-Demand Scenario

        4.3.6. Antibacterial Drugs Market Outlook

        4.3.7. Anti-Bacterial Drugs Pipeline Analysis 

Chapter 5. Global Antibacterial Drugs Market Analysis, by Drug Class, 2017 – 2030

    5.1. Key Findings

    5.2.  Definition

    5.3. Introduction

    5.4. Global Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2030

    5.5. Global Antibacterial Drugs Market Analysis, by Drug Class

        5.5.1. β-lactam 

        5.5.2. Quinolones

        5.5.3. Macrolides

        5.5.4. Tetracycline

        5.5.5. Aminoglycoside

        5.5.6. Sulfonamide

        5.5.7. Phenicols

        5.5.8. Others

    5.6. Global Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    5.7. Global Antibacterial Drugs Market Forecast, by Drug Class

    5.8. Key Trends

Chapter 6. Global Antibacterial Drugs Market Analysis, by Routes of Administration 

    6.1. Key Findings

    6.2. Definitions

    6.3. Introduction

    6.4. Global Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2030

    6.5. Global Antibacterial Drugs Market Analysis, by Routes of Administration

        6.5.1. Enteral

        6.5.2. Parenteral

        6.5.3. Others 

    6.6.  Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

    6.7. Global Antibacterial Drugs Market Forecast, by Routes of Administration

Chapter 7. Global Antibacterial Drugs Market Analysis, by Channels of Distribution 

    7.1.  Key Findings

    7.2. Definitions

    7.3. Introduction 

    7.4. Global Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2030

    7.5. Global Antibacterial Drugs Market Analysis, by Channels of Distribution

        7.5.1. Hospital Pharmacies

        7.5.2. Drug Stores & Retail Pharmacies

        7.5.3. Online Sales

    7.6. Global Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution

    7.7. Global Antibacterial Drugs Market Forecast, by Channels of Distribution

    7.8. Key Trends

Chapter 8. Global Antibacterial Drugs Market Analysis, by Region

    8.1.  Key Findings 

    8.2. Introduction

    8.3. Global Antibacterial Drugs Market Value Share Analysis, by Region, 2018 and 2030

    8.4. Global Antibacterial Drugs Market Attractiveness Analysis, by Region

    8.5. Global Antibacterial Drugs Market Forecast, by Region, 2017–2030

Chapter 9. North America Antibacterial Drugs Market Analysis

    9.1. North America Antibacterial Drugs Market Overview

    9.2. North America Antibacterial Drugs Market Forecast, Country wise, 2017–2030

    9.3. North America Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2030

    9.4. North America Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    9.5. North America Antibacterial Drugs Market Forecast, by Drug Class, 2017–2030

    9.6. North America Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2030

    9.7. North America Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

    9.8. North America Antibacterial Drugs Market Forecast, by Routes of Administration, 2017–2030

    9.9. North America Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2030

    9.10.  North America Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution

    9.11.  North America Antibacterial Drugs Market Forecast, by Channels of Distributions, 2017–2030

    9.12.  Key Trends

Chapter 10. Europe Antibacterial Drugs Market Analysis

    10.1.  Europe Antibacterial Drugs Market Overview

    10.2.  Europe Antibacterial Drugs Market Forecast, Country wise, 2017–2030

    10.3.  Europe Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2030

    10.4.  Europe Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    10.5.  Europe Antibacterial Drugs Market Forecast, by Drug Class, 2017–2030

    10.6.  Europe Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2030

    10.7.  Europe Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration, 

    10.8.  Europe Antibacterial Drugs Market Forecast, by Routes of Administration, 2017–2030

    10.9.  Europe Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2030

    10.10.  Europe Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution 

    10.11.  Europe Antibacterial Drugs Market Forecast, by Channels of Distributions, 2017–2030

    10.12.  Key Trends

Chapter 11.  Asia Pacific  Antibacterial Drugs Market Analysis

    11.1.  Asia Pacific  Antibacterial Drugs Market Overview

    11.2.  Asia Pacific  Antibacterial Drugs Market Forecast, Country wise, 2017–2030

    11.3.  Asia Pacific  Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2030

    11.4.  Asia Pacific  Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    11.5.  Asia Pacific  Antibacterial Drugs Market Forecast, by Drug Class, 2017–2030

    11.6.  Asia Pacific  Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2030

    11.7.  Asia Pacific  Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

    11.8.  Asia Pacific  Antibacterial Drugs Market Forecast, by Routes of Administration, 2017–2030

    11.9.  Asia Pacific  Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2030

    1.1.  Pacific  Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution 

    11.10. Asia Pacific Antibacterial Drugs Market Forecast, by Channels of Distributions, 2017–2030

    11.11. Key Trends

Chapter 12.  Latin America  Antibacterial Drugs Market Analysis

    12.1.  Latin America  Antibacterial Drugs Market Overview

    12.2.  Latin America  Antibacterial Drugs Market Forecast, Country wise, 2017–2030

    12.3.  Latin America  Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2030

    12.4.  Latin America  Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    12.5.  Latin America  Antibacterial Drugs Market Forecast, by Drug Class, 2017–2030

    12.6.  Latin America  Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2030

    12.7.  Latin America  Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

    12.8.  Latin America  Antibacterial Drugs Market Forecast, by Routes of Administration, 2017–2030

    12.9.  Latin America  Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2030

    12.10.  Latin America Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution

    12.11.  Latin America Antibacterial Drugs Market Forecast, by Channels of Distributions, 2017–2030

    12.12.  Key Trends

Chapter 13.  Middle East & Africa Antibacterial Drugs Market Analysis

    13.1.  Middle East & Africa   Antibacterial Drugs Market Overview

    13.2.  Middle East & Africa   Antibacterial Drugs Market Forecast, Country wise, 2017–2030

    13.3.  Middle East & Africa  Antibacterial Drugs Market Value Share Analysis, by Drug Class, 2018 and 2030

    13.4.  Middle East & Africa  Antibacterial Drugs Market Attractiveness Analysis, by Drug Class

    13.5.  Middle East & Africa  Antibacterial Drugs Market Forecast, by Drug Class, 2017–2030

    13.6.  Middle East & Africa  Antibacterial Drugs Market Value Share Analysis, by Routes of Administration, 2018 and 2030

    13.7.  Middle East & Africa Antibacterial Drugs Market Attractiveness Analysis, by Routes of Administration

    13.8.  Middle East & Africa Antibacterial Drugs Market Forecast, by Routes of Administration, 2017–2030

    13.9.  Middle East & Africa Antibacterial Drugs Market Value Share Analysis, by Channels of Distribution, 2018 and 2030

    13.10. Middle East & Africa Antibacterial Drugs Market Attractiveness Analysis, by Channels of Distribution

    13.11.  Middle East & Africa Antibacterial Drugs Market Forecast, by Channels of Distributions, 2017–2030

    13.12.  Key Trends

Chapter 14.  Competition Landscape

    14.1.  Leading Antibacterial Drugs Sales Analysis 

    14.2.  Competition Matrix

    14.3.  Company Profiles 

        14.3.1. Bayer AG

            14.3.1.1. Company Description

            14.3.1.2. Business Overview

            14.3.1.3. SWOT Analysis

            14.3.1.4. Strategic Overview

        14.3.2. Pfizer Inc.

            14.3.2.1. Company Description

            14.3.2.2. Business Overview

            14.3.2.3. SWOT Analysis

            14.3.2.4. Strategic Overview

        14.3.3. Sanofi

            14.3.3.1. Company Description

            14.3.3.2. Business Overview

            14.3.3.3. SWOT Analysis

            14.3.3.4. Strategic Overview

        14.3.4. GlaxoSmithKline plc

            14.3.4.1. Company Description

            14.3.4.2. Business Overview

            14.3.4.3. SWOT Analysis

            14.3.4.4. Strategic Overview

        14.3.5. Merck & Co., Inc.

            14.3.5.1. Company Description

            14.3.5.2. Business Overview

            14.3.5.3. SWOT Analysis

            14.3.5.4. Strategic Overview

        14.3.6. AstraZeneca

            14.3.6.1. Company Description

            14.3.6.2. Business Overview

            14.3.6.3. SWOT Analysis

            14.3.6.4. Strategic Overview

        14.3.7. Johnson and Johnson Services, Inc.

            14.3.7.1. Company Description

            14.3.7.2. Business Overview

            14.3.7.3. SWOT Analysis

            14.3.7.4. Strategic Overview

        14.3.8. Bristol-Myers Squibb Company

            14.3.8.1. Company Description

            14.3.8.2. Business Overview

            14.3.8.3. SWOT Analysis

            14.3.8.4. Strategic Overview

        14.3.9. Novartis AG

            14.3.9.1. Company Description

            14.3.9.2. Business Overview

            14.3.9.3. SWOT Analysis

            14.3.9.4. Strategic Overview

        14.3.10. Allergen 

            14.3.10.1. Company Description

            14.3.10.2. Business Overview

            14.3.10.3. SWOT Analysis

            14.3.10.4. Strategic Overview